Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
5.120
+0.110 (+2.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Coya Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
January 18, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
January 16, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
January 05, 2024
From
Coya Therapeutics, Inc.
Via
Business Wire
Analyst Expectations for Coya Therapeutics's Future
July 17, 2023
Via
Benzinga
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
December 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
December 13, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
December 12, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces $26.5 Million Private Placement
December 06, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
December 06, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
December 04, 2023
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.
Via
MarketBeat
Topics
Bonds
Exposures
Debt Markets
12 Health Care Stocks Moving In Friday's After-Market Session
December 01, 2023
Via
Benzinga
These biotechs targeting multiple neurodegenerative diseases
December 01, 2023
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.
Via
MarketBeat
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
November 08, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Announces Acceptance of Oral Presentation, “Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer’s Disease: A Phase 1 Feasibility Study,” at the 18th International Conference on Alzheimer’s and Parkinson’s Disease in Lisbon
October 27, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)
October 09, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
October 05, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
October 03, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present at the LD Micro Investor Conference
September 27, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
September 22, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
How The Same Treatments May Work For Multiple Neurodegenerative Diseases
September 21, 2023
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
September 07, 2023
Via
Benzinga
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases
September 07, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies
August 31, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023
August 25, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors
August 21, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
August 08, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
August 03, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
July 19, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation
July 17, 2023
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients
Via
Benzinga
Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease
July 17, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.